Glancy Prongay Wolke & Rotter LLP continues its investigation into Replimune Group Inc. for possible violations of federal securities laws. The investigation follows a July 28, 2026 FDA briefing document release that deemed the single-arm mid-stage study for Replimune's skin cancer drug RP1 as not interpretable, confoundeding interpretation of efficacy results and limiting the FDA's ability to verify reported results. On that news, Replimune's stock price fell $3.27, or 37.89%, in intraday trading, injuring investors. The law firm urges shareholders who lost money to contact them to discuss potential claims.
Replimune Group IncFDA briefing document deemed RP1 study not interpretable, causing stock to drop 37.89%